EUROPE DEVICE GUIDE > Drug-Eluting Stents

Company Name Product Name Drug Delivered Material Used Polymer Type Maximum Guidewire Size (inch) Introducer Size (F) Stent Diameter (mm) Stent Length (mm) Delivery System Length (cm) CE Indications
Abbott Vascular Xience Prime BTK Everolimus Cobalt chromium Fluorinated copolymer 0.014 4 2.5, 3, 3.5, 4 28, 38 143 Indicated for improving peripheral luminal diameter in the following: the treatment of severe claudication or CLI due to infrapopliteal occlusive lesions
Alvimedica Cre8 BTK Amphilimus (sirolimus + fatty acid) Cobalt chromium Polymer-free 0.014 4 2.25–4.5 8–46 142 Peripheral/BTK
Biosensors International BioMatrix Flex BTK Drug Eluting Peripheral Stent Biolimus A9 pharmaceutical ingredient Stainless steel Biodegradable polymer coating 15.6 μg/mm stent length 0.014 5, 6 2.25, 2.5, 2.75, 3, 3.5, 4 8, 11, 14, 18, 24, 28, 33, 36 142 Indicated for improving infrapopliteal luminal diameter for the treatment of occlusive lesions BTK and above the ankle that lead to severe claudication or CLI; treated infrapopliteal arteries must have a reference diameter ranging between 2.25–4 mm
Boston Scientific Corporation Eluvia Drug-Eluting Vascular Stent System Paclitaxel Nitinol Polymer-based technology with proven biocompatibility 0.035 6 6–7 40, 60, 80, 100, 120, 150 75, 130 SFA and/or PPA
Boston Scientific Corporation Promus Element Plus BTK Everolimus-Eluting Platinum Chromium Stent System Everolimus Platinium chromium Fluorinated copolymer 0.014 (0.36 mm) 4 2.25, 2.5, 3, 3.5, 4 28, 38 144 Infrapopliteal lesions
Cook Medical Zilver PTX Paclitaxel Nitinol No polymer 0.035 6 5–8 40, 60, 80, 100, 120 80, 125 Above-the-knee femoropopliteal arteries
iVascular Angiolite BTK Sirolimus Cobalt chromium Biostable 0.014 5 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5 9, 14, 16, 19, 24, 29, 34, 39 142 Indicated for treating chronic and acute arterial lesions in the lower limbs below the knee (BTK), as well as popliteal and infrapopliteal lesions with reference vessel diameters of between 2 and 4.5 mm, with the aim of increasing the internal diameter of an artery and consequently improving blood flow in the following cases: severe claudication and critical limb ischemia.

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.